ABUS at a glance
Arbutus Biopharma Corp (ABUS, SEC CIK 1447028) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 21, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Arbutus Biopharma Corp (ABUS) shares worth $281.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $14.1M
- +128.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $281.7M · +1 vs prior quarter
- Latest 8-K
- Aug 21, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Moderna settlement: $950.0M payment, including $178.4M received by Arbutus
- Potential $1.3B contingent payment tied to favorable §1498 appeal ruling
- Near-term outlook: Phase 2b imdusiran protocol after FDA alignment; potential Genevant dividend and shareholder capital return in Q3 2026
Risk Factors
- No material changes in risk factors from the December 31, 2025 Form 10-K
- Carried-forward regulatory, legal, operational, competitive, and financial risks unchanged from the annual filing
- No new quarter-specific risk trigger identified in the filing
AI summary of the ABUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Planned modified Dutch auction tender offer to repurchase up to $230 million of common shares
- Proposed purchase price range of $5.00–$5.75 per share
Item EX-99.1: Item EX-99.1
- Planned $230M share repurchase via modified Dutch auction at $5.00–$5.75 per share
- Funding from cash on hand, returning proceeds from the Moderna settlement to shareholders
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 12, 2026
Item 8.01: Other Events
- Patent-enforcement lawsuits filed against Pfizer/BioNTech and affiliates over lipid nanoparticle technology
- Genevant dividend expected in Q3 2026, but timing and terms remain uncertain
Item 1.02: Termination of a Material Definitive Agreement
- One-time CEO bonus equal to 1.5% of Arbutus’ noncontingent Moderna settlement share, payable by end-July 2026
- CEO entitled to 2.0% of remaining Moderna-related proceeds, including §1498 appeal or U.S. government litigation recoveries
AI summaries of ABUS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABUS
Don't miss the next ABUS filing
- Alerts as it files. A push when ABUS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABUS, by share count.
- Ask anything. An AI agent that reads every ABUS filing and answers with sources.
ABUS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Roivant Sciences Ltd. | D | Oct 1, 2026 | 8,967,383 | $5.00 |
| Nguyen Tuan | M | Sep 18, 2026 | 265,625 | - |
| Androski Lindsay | M | Sep 18, 2026 | 10,456 | $4.39 |
| Nguyen Tuan | M | Sep 18, 2026 | 265,625 | $3.49 |
| Nguyen Tuan | M | Sep 18, 2026 | 27,475 | $4.39 |
| Androski Lindsay | M | Sep 18, 2026 | 116,408 | $3.20 |
| Androski Lindsay | M | Sep 18, 2026 | 10,456 | - |
| Androski Lindsay | F | Sep 18, 2026 | 82,527 | $5.07 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.2M | $14.1M |
| Operating Income | - | -$76.3M | -$38.2M |
| Net Income | -$72.8M | -$69.9M | -$33.5M |
| Op. Margin | - | -1236.7% | -271.0% |
| Net Margin | - | -1133.0% | -237.9% |
| Balance Sheet | |||
| Total Assets | $144.4M | $131.7M | $94.6M |
| Equity | - | $97.4M | $76.6M |
| ROE | - | -71.8% | -43.7% |
| Per Share | |||
| EPS | $-0.44 | $-0.38 | $-0.17 |
| Cash Flow | |||
| Operating CF | - | -$64.8M | -$39.6M |
| CapEx | $1.0M | $182K | $0 |
Source: XBRL data in Arbutus Biopharma Corp (ABUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ABUS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $281.7M |
| Q1 2026 | 24 | $274.4M |
| Q4 2025 | 20 | $297.6M |
| Q3 2025 | 22 | $266.6M |
| Q2 2025 | 26 | $181.8M |
| Q1 2025 | 22 | $149.7M |
| Q4 2024 | 17 | $55.0M |
| Q3 2024 | 12 | $27.5M |
- Goldman Sachs Group+2.41M (+219%)
- State Street Corp+1.53M (+24%)
- Bank of America Corp+962.6K (+57%)
- BlackRock+799.1K (+6%)
- Vanguard Capital Management LLC+321.8K (+5%)
- Morgan Stanley−8.19M (-32%)
- Citadel Advisors LLC−272.4K (-40%)
- Citigroup−19.2K (-2%)
- PNC Financial Services−179 (-10%)
- U.S. Bancorp−94 (-6%)
- Two Sigma Investments+85.0K
- Allstate+44.2K
- Ameriprise Financial+10.5K
- Millennium Management−642.4K
- Raymond James Financial−191.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 168 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ABUS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| SC 13G | Sep 4, 2026 | - | - | |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 10-K | Mar 23, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 23, 2026 | - | - | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 8-K | Feb 20, 2026 | - | - | |
| 8-K | Feb 6, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 8-K | Jan 16, 2026 | - | - | |
| 8-K | Dec 11, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ABUS SEC filings: frequently asked questions
Which institutions hold ABUS stock?
As of June 30, 2026, the largest Arbutus Biopharma Corp (ABUS) holders among the 13F filers tracked by SignalX were Morgan Stanley ($85.0 million), BlackRock ($66.1 million), State Street Corp ($37.8 million), Vanguard Capital Management LLC ($33.7 million), Goldman Sachs Group ($16.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ABUS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17. The figures come from the XBRL data in the 10-K.
What did ABUS report in its latest 8-K?
Arbutus Biopharma Corp (ABUS) filed an 8-K on August 21, 2026 reporting Item 8.01 (Other Events). Planned modified Dutch auction tender offer to repurchase up to $230 million of common shares.
What are the latest ABUS SEC filings?
Arbutus Biopharma Corp (ABUS) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 21, 2026 and a Form 4 insider filing on October 5, 2026.
What is ABUS's SEC CIK number?
Arbutus Biopharma Corp (ABUS)'s SEC Central Index Key (CIK) is 1447028. EDGAR lists every ABUS filing under that number.
Ask anything about ABUS
The research agent reads ABUS's filings, financials, insider trades and 13F holders, then answers with sources.